首页> 外文OA文献 >53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)

【2h】

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)

机译：53. Tucatinib VS安慰剂加入到葡萄球菌和Capecitabine，用于患有先前治疗的Her2 +转移性乳腺癌（MBC）的患者（MBC）（BM）（HER2CLIMB）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nancy Lin; Rashmi Murthy; Carey Anders; Virginia Borges; Sara Hurvitz; Sherene Loi; Vandana Abramson; Philippe Bedard; Mafalda Oliveira; Amelia Zelnack; Michael DiGiovanna; Thomas Bachelot; A Jo Chien; Ruth O’Regan; Andrew Wardley; Volkmar Mueller; Lisa Carey; Suzanne McGoldrick; Xuebei An; Eric Winer;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Tucatinib与Capecitabine和Trastuzumab相结合，为预处理Her2阳性转移性乳腺癌有和没有脑转移的患者（Her2Climb）
2. 490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review [J] . V.Diéras, M.N.Guilhaume, M.Fall, European Journal of Cancer Supplements . 2010,第3期

机译：490用曲妥珠单抗（T）治疗的HER2阳性（HER2 +）转移性乳腺癌患者（MBC）的长期生存和脑转移发生率：基于机构的评价
3. 490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review [J] . V.Diéras, M.N.Guilhaume, M.Fall, European Journal of Cancer Supplements . 2010,第3期

机译：490用曲妥珠单抗（T）治疗的HER2阳性（HER2 +）转移性乳腺癌患者（MBC）的长期生存和脑转移发生率：基于机构的评价
4. Minimally toxic approach for treatment of cutaneous breast cancer metastases: Capecitabine-enhanced photodynamic therapy [C] . Sanjay Anand, Taylor Bullock, Edward V. Maytin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XXVI . 2017

机译：皮肤癌转移的最小毒性方法：卡培他滨增强的光动力疗法
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) [O] . Nancy Lin, Rashmi Murthy, Carey Anders, 2020

机译：53. Tucatinib VS安慰剂加入到葡萄球菌和Capecitabine用于患有先前治疗的Her2 +转移性乳腺癌（MBC）的患者（MBC）（BM）（HER2CLIMB）
7. PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY) [O] . Sofrygin O, Delea T, Tappenden P, 2008

机译：PCN9比例风险（PH）威布尔模型在分析曲妥珠单抗（TZ）耐药性ERBB2 +（HER2 +）转移性乳腺癌（MBC）患儿的无进展生存率（PFS）和总生存率（OS）方面的有效性C）仅卡西他滨（仅C）
8. Rapid Translation of a Novel and Potent Vaccine in HER2+ Metastatic Breast Cancer Patients. [R] . Lyerly, H. K. 2013

机译：一种新型强效疫苗在HER2 +转移性乳腺癌患者中的快速翻译。

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)

著录项

相似文献

相关主题

期刊订阅